These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33469580)

  • 1. CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells.
    Ma M; Badeti S; Chen CH; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
    bioRxiv; 2021 Jan; ():. PubMed ID: 33469580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
    Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
    Front Immunol; 2021; 12():652223. PubMed ID: 34367128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S309-CAR-NK cells bind the Omicron variants
    Ma MT; Jiang Q; Chen C-H; Badeti S; Wang X; Zeng C; Evans D; Bodnar B; Marras SAE; Tyagi S; Bharaj P; Yehia G; Romanienko P; Hu W; Liu S-L; Shi L; Liu D
    J Virol; 2024 Jun; 98(6):e0003824. PubMed ID: 38767356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells.
    Ma M; Badeti S; Geng K; Liu D
    bioRxiv; 2020 Aug; ():. PubMed ID: 32817942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
    Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
    Front Immunol; 2021; 12():763460. PubMed ID: 35003077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.
    Lu T; Ma R; Dong W; Teng KY; Kollath DS; Li Z; Yi J; Bustillos C; Ma S; Tian L; Mansour AG; Li Z; Settles EW; Zhang J; Keim PS; Barker BM; Caligiuri MA; Yu J
    Nat Commun; 2022 May; 13(1):2576. PubMed ID: 35546150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional analysis of a potent sarbecovirus neutralizing antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    bioRxiv; 2020 Apr; ():. PubMed ID: 32511354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage.
    Cheng YW; Chao TL; Li CL; Wang SH; Kao HC; Tsai YM; Wang HY; Hsieh CL; Lin YY; Chen PJ; Chang SY; Yeh SH
    mBio; 2021 Aug; 12(4):e0058721. PubMed ID: 34311586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.
    Lee CY; Amrun SN; Chee RS; Goh YS; Mak TM; Octavia S; Yeo NK; Chang ZW; Tay MZ; Torres-Ruesta A; Carissimo G; Poh CM; Fong SW; Bei W; Lee S; Young BE; Tan SY; Leo YS; Lye DC; Lin RT; Maurer-Stroh S; Lee B; Wang CI; Renia L; Ng LF
    Clin Transl Immunology; 2021; 10(2):e1241. PubMed ID: 33628442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types.
    Daniloski Z; Jordan TX; Ilmain JK; Guo X; Bhabha G; tenOever BR; Sanjana NE
    Elife; 2021 Feb; 10():. PubMed ID: 33570490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.
    Zhang L; Jackson CB; Mou H; Ojha A; Rangarajan ES; Izard T; Farzan M; Choe H
    bioRxiv; 2020 Jun; ():. PubMed ID: 32587973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective chimeric antigen receptor T cells against SARS-CoV-2.
    Guo X; Kazanova A; Thurmond S; Saragovi HU; Rudd CE
    iScience; 2021 Nov; 24(11):103295. PubMed ID: 34693218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Founder Effect Led Early SARS-CoV-2 Transmission in Spain.
    Díez-Fuertes F; Iglesias-Caballero M; García-Pérez J; Monzón S; Jiménez P; Varona S; Cuesta I; Zaballos Á; Jiménez M; Checa L; Pozo F; Pérez-Olmeda M; Thomson MM; Alcamí J; Casas I
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33127745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.